We are excited to announce that Eagle IP will be returning as a sponsor and exhibitor at the upcoming Life Sciences Patent Network (LSPN) North America Spring conference in Boston. Our President and Managing Director, Ms. Jennifer Che, is one of the distinguished speakers at the event. Organized by Life Sciences Intellectual Property Review, this event will take place on May 6-7, 2025, at the Hyatt Regency Boston located at One Avenue de Lafayette, Boston, MA 02111.

Come join us there and meet us at our booth!

Every year, LSPN brings together experts from pharmaceutical, biotech, and medtech industries to discuss innovation and IP protections. The conference covers patentability, eligibility, prosecution, and litigation, offering insights for the entire patent protection lifecycle in the US.

For more information about the conference and to complete your registration, please visit: https://www.lspnnorthamerica.com

If you won’t be able to attend LSPN but will be in Boston and would like to schedule a meeting, please let us know. We would be happy to arrange a convenient time to connect.

We are looking forward to seeing you in Boston!

Our Past Events

Recommended Insights

china-joins-two-wipo-treaties

China Joins Two WIPO Treaties, the Hague System and the Marrakesh Treaty

11 February 2022
It has been two challenging years, yet there are many reasons to still have hope. We wish you a blessed Lunar New Year as we welcome the year of the Tiger. We wanted to highlight a few new developments in China. China has joined the Hague System for the International Registration of Industrial Designs, submitting […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 3: The 15-Day Mailing Period is Mostly Going Away

28 February 2024
A Closer Look at the New Presumed Receipt Date Calculation Background China has finally released the long-awaited Patent Law Implementation Regulations (“Regulations”) and associated "Patent Examination Guidelines" (“Guidelines”, similar to the United States' MPEP) which provide further clarity and details of the new Chinese patent law. Today’s article will focus on changes that impact how […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

14 July 2020
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

12 April 2023
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]
Top crossarrow-right